SCYNEXIS Priced, Nasdaq: SCYX
Biotech developing treatments for life-threatening fungal infections.
Industry: Health Care
First Day Return: -10.0%
Industry: Health Care
SCYX
Biotech developing treatments for life-threatening fungal infections.
| IPO Data | |
|---|---|
| IPO File Date | 02/27/2014 |
| Offer Price | $10.00 |
| Price Range $10.00 - $10.00 | |
| Offer Shares (mm) | 6.2 |
| Deal Size ($mm) | $62 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 05/01/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $62 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Durham, NC, United States |
| Founded | 1999 |
| Employees at IPO | 90 |
| Website www.scynexis.com | |
IPO News for SCYNEXIS
SCYNEXIS (SCYX) Performance
